beta-adrenergic receptor agonist

From Aaushi
Jump to navigation Jump to search

Adverse effects

Drug interactions

Mechanism of action

  • stimulation of cAMP formation in selected cell population

More general terms

More specific terms

Additional terms

Component of

References

  1. Mayo Internal Medicine Board Review, 1998-99, Prakash UBS (ed) Lippincott-Raven, Philadelphia, 1998, pg 741
  2. 2.0 2.1 Prescriber's Letter 12(9): 2005 The Safety of Long-Acting Beta-2 Agonists in Patients with Asthma Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=210907&pb=PRL (subscription needed) http://www.prescribersletter.com
    US Department of Health and Human Services. National Institutes of Health. National Heart, Lung and Blood Institute. Expert Panel Report: Guidelines for the Diagnosis and Management of Asthma-Update on selected topics 2002.
  3. Salpeter SR et al, Meta-analysis: Effect of long-acting beta agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med 2006; 144:904 PMID: https://www.ncbi.nlm.nih.gov/pubmed/16754916
    Glassroth J The role of long-acting beta-agonists in the management of asthma. Analysis, meta-analysis, and more analysis, Ann Intern Med 2006; 144:936 PMID: https://www.ncbi.nlm.nih.gov/pubmed/16754915
  4. Bateman E et al, Effects of adding salmeterol in inhaled corticosteroids on serious asthma-related events. Ann Intern Med 2008, June 3 PMID: https://www.ncbi.nlm.nih.gov/pubmed/18523132
    Weiss KB Drug safety and salmeterol: The controversy continues. Ann Intern Med 2008, June 3 PMID: https://www.ncbi.nlm.nih.gov/pubmed/18523132